GlassScriptPhysician profile
Barbara Lee Bellfield
NPI 1295915825
$19,859.92
in general payments reported to CMS, 2019-2025
50 companies · $4,816 in 2025
The $4,816 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,830 · 2022: $3,789 · 2023: $3,288 · 2024: $4,137 · 2025: $4,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,900 · Long Term Medical Supply Or Device Loan: $2,250 · Education: $91.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,899.76 |
| Long Term Medical Supply Or Device Loan | $2,249.91 |
| Education | $91.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,417.52 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,507.13 | 2021-2025 | Imfinzi, Enhertu, Lynparza |
| Janssen Biotech, INC. | $1,345.27 | 2021-2025 | Darzalex, Rybrevant, Tecvayli |
| Incyte Corporation | $1,110.58 | 2022-2025 | Jakafi, Pemazyre, Monjuvi |
| Merck Sharp & Dohme LLC | $944.99 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $815.97 | 2021-2025 | |
| Celgene Corporation | $799.14 | 2022-2025 | Reblozyl, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $715.00 | 2022-2025 | Alunbrig, Iclusig, Fruzaqla |
| Eisai INC. | $630.65 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $550.54 | 2021-2025 | Opdivo, Opdualag |
| Seagen INC. | $415.32 | 2021-2023 | Tukysa, Adcetris |
| Lilly USA, LLC | $410.00 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $391.25 | 2021-2024 | Zejula, Jemperli |
| Daiichi Sankyo INC. | $386.76 | 2021-2025 | Enhertu |
| Astellas Pharma US INC | $329.98 | 2022-2025 | Xtandi |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $278.30 | 2021-2025 | |
| Exelixis INC. | $259.71 | 2023-2025 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.17 | 2021-2025 | Gilotrif |
| Amgen INC. | $225.30 | 2021-2023 | Lumakras, Blincyto, Kyprolis |
| Abbvie INC. | $206.11 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $205.12 | 2022-2025 | Xpovio |
| Aveo Pharmaceuticals, INC. | $202.76 | 2022-2024 | Fotivda |
| Sun Pharmaceutical Industries INC. | $196.59 | 2021-2025 | Yonsa |
| Genzyme Corporation | $190.85 | 2022-2023 | |
| Sobi, INC | $189.29 | 2022-2025 | |
| Puma Biotechnology, INC. | $176.72 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $165.40 | 2022-2024 | Libtayo |
| Tersera Therapeutics LLC | $161.84 | 2022-2024 | Xermelo, Zoladex |
| Agios Pharmaceuticals, INC. | $158.11 | 2024-2025 | Pyrukynd |
| Jazz Pharmaceuticals INC. | $121.13 | 2024-2025 | |
| Stemline Therapeutics INC. | $98.34 | 2024-2025 | Orserdu, Elzonris |
| Legend Biotech USA INC. | $94.93 | 2024-2025 | Carvykti |
| Mirati Therapeutics, INC. | $93.98 | 2023-2024 | Krazati |
| Emd Serono, INC. | $90.95 | 2024-2025 | |
| Taiho Oncology, INC. | $86.47 | 2023-2025 | |
| Morphosys, US INC. | $78.47 | 2022-2023 | Monjuvi |
| Genmab U.S., INC. | $78.25 | 2024 | Epkinly |
| Pharmaessentia USA Corporation | $74.50 | 2025 | Besremi |
| Array Biopharma INC | $62.70 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
| Alexion Pharmaceuticals, INC. | $47.96 | 2023 | Ultomiris |
| Progenics Pharmaceuticals, INC. | $46.12 | 2025 | |
| Azurity Pharmaceuticals, INC. | $44.94 | 2025 | Danziten, Vivimusta |
| Gilead Sciences, INC. | $43.21 | 2023-2024 | Trodelvy |
| Dova Pharmaceuticals | $42.83 | 2021 | |
| Immunogen, INC. | $34.55 | 2023 | Elahere |
| Beigene USA, INC. | $26.52 | 2024 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $23.99 | 2023 | |
| Myriad Genetic Laboratories, INC. | $18.01 | 2021 | |
| Accord Healthcare, INC. | $17.88 | 2024 | |
| Deciphera Pharmaceuticals INC. | $17.82 | 2025 | Romvimza, Qinlock |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Bellfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.